On a year-on-year basis, the company’s total revenue has contracted by 15 per cent to ₹3,856 crore from ₹4,519 crore. However, on a like-for-like basis, consolidated revenue experienced an uptick of 7 per cent. Read more: https://pharma.economictimes.indiatimes.com/news/financial-performance/biocons-profit-struggles-continue-in-q3-net-profit-plunges-96/117776903